Addition of tiotropium effective in poorly controlled asthma

September 4, 2012
Addition of tiotropium effective in poorly controlled asthma
For patients with poorly controlled asthma, the addition of tiotropium to standard therapy is beneficial, according to a study published online Sept. 3 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the European Respiratory Society, held from Sept. 1 to 5 in Vienna.

(HealthDay)—For patients with poorly controlled asthma, the addition of tiotropium to standard therapy is beneficial, according to a study published online Sept. 3 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the European Respiratory Society, held from Sept. 1 to 5 in Vienna.

Huib A.M. Kerstjens, M.D., from the University of Groningen in the Netherlands, and colleagues compared the effect of adding tiotropium or placebo delivered by soft-mist inhaler once a day for 48 weeks on lung function and in two replicate . The trials involved 912 patients with asthma (mean age, 53 years) who were receiving inhaled glucocorticoids and long-acting beta-agonists (LABAs). All participants were symptomatic and had a history of at least one severe exacerbation in the previous year.

The researchers found that the mean baseline forced expiratory volume in one second () was 62 percent of the predicted value. In the two trials, the mean change in peak FEV1 was significantly greater with tiotropium than with placebo. In both trials, the pre-dose (trough) FEV1 also improved significantly with tiotropium compared with placebo. There was an increase in the time to first exacerbation with the addition of tiotropium (282 versus 226 days), and a significant overall reduction in the risk of severe exacerbation (hazard ratio, 0.79). Adverse events were similar between the groups and there were no deaths in either group.

"In patients with poorly controlled asthma despite use of inhaled glucocorticoids and LABAs, the addition of tiotropium significantly increased the time to the first severe exacerbation and provided modest sustained bronchodilation," the authors write.

Several authors disclosed to pharmaceutical companies, including Boehringer Ingelheim and Pfizer, both of which funded the study and manufacture tiotropium.

Explore further: Researchers question safety of mist inhalers for delivering common drug for chronic lung disease

More information: Abstract
Full Text
Editorial
More Information

Related Stories

Late-breaking clinical trials

May 17, 2011

Results from C91 "Late-Breaking Clinical Trials" on Tuesday afternoon, May 17, will bring new light to clinical problems and potential treatments. While five examine possible new therapies for people with asthma (pregnant ...

Recommended for you

Nature study suggests new therapy for Gaucher disease

February 22, 2017

Scientists propose in Nature blocking a molecule that drives inflammation and organ damage in Gaucher and maybe other lysosomal storage diseases as a possible treatment with fewer risks and lower costs than current therapies.

T cells support long-lived antibody-producing cells

February 21, 2017

If you've ever wondered how a vaccine given decades ago can still protect against infection, you have your plasma cells to thank. Plasma cells are long-lived B cells that reside in the bone marrow and churn out antibodies ...

Understanding how HIV evades the immune system

February 21, 2017

Monash University (Australia) and Cardiff University (UK) researchers have come a step further in understanding how the human immunodeficiency virus (HIV) evades the immune system.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.